PD-L1 immune suppression in cancer: Tumor cells or host cells?
Open Access
- 12 May 2017
- journal article
- opinion
- Published by Taylor & Francis in OncoImmunology
- Vol. 6 (7) , e1325982
Abstract
Four recent publications reported the role of PD-L1 expression on host versus malignant cells within the tumor for PD-1/PD-L1 checkpoint blockade therapy. All four research groups harmoniously report: PD-L1 expressed by both host as well as tumor cells are capable of suppressing T cell functions. Thus, checkpoint therapy can be effective, if malignant cells do not express PD-L1.Keywords
This publication has 4 references indexed in Scilit:
- PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicityJournal of Experimental Medicine, 2017
- PD-L1 expression on malignant cells is no prerequisite for checkpoint therapyOncoImmunology, 2017
- Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in miceNature Communications, 2017
- Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune EscapeCancer Immunology Research, 2017